Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Pulls Abbott’s Cylert From Market Due To Liver Toxicity

This article was originally published in The Pink Sheet Daily

Executive Summary

The ADHD drug will no longer be available after current supplies of pemoline generics are exhausted. Abbott stopped marketing the drug in May, citing low sales.

You may also be interested in...

Abbott Says Decision To Discontinue Cylert Stems From Demand, Not Safety

Significant decline in pemoline sales is reason behind the ADHD agent's discontinuation, not liver safety issues raised in a Public Citizen petition to FDA, Abbott says. Public Citizen seeks withdrawal of Cylert and generics; the petition references two analyses of pemoline conducted by FDA drug safety officer Graham.

India Highlights "Public Interest" To Reign In Prices For Non-Scheduled Drugs

Dr. Reddy's, GSK, Ranbaxy and UCB among manufacturers that could see prices reduced under government order that reflects issues raised in Gleevec patent dispute.

Indian Health Minister Asks Novartis to Stand Down On Gleevec Patent Fight

Indian regulators threaten compulsory licensing of the oncologic, but Novartis says it has no plans to end its bid for patent protection.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts